A new hazelnut development program in the Lake States

Paper presented at the 12th North American Agroforesty Conference, which was held June 4-9, 2011 in Athens, Georgia.In Ashton, S. F., S.W. Workman, W.G. Hubbard and D.J. Moorhead, eds. Agroforestry: A Profitable Land Use. Proceedings, 12th North American Agroforestry Conference, Athens, GA, June 4-9, 2011.Hazelnut is an intriguing new crop for the Lake States, suited for use as an oilseed and as an edible nut. Several researchers and hobby breeders have attempted to develop this crop for the Lake States with some current small-scale commercial adoption; however, the crop is still in its infancy. A group of researchers, extension specialists and growers are assisting in the development of a hazelnut industry in Wisconsin and Minnesota. Activities include 1) aiding farmers in selecting plant material from existing plantings of seed origin hybrids for their use or broader adoption, 2) screening wild American hazelnut for high-performing plantsfor use by breeders or as potential crop plants, 3) developing clonal propagation methods and 4) providing outreach activities to those currently growing and those interested in growing hazelnuts. We plan to discuss our results to date emphasizing clonal propagation research and the protocols and results of the schreening program for wild American hazelnuts.Mike Demchik (1), Brent McCown (2), Jason Fischbach (3), Anthony Kern (4) and Eric Zeldin (5) ; 1. College of Natural Resources, University of Wisconsin Stevens Point. 2. Horticulture, University of Wisconsin Madison. 3. University of Wisconsin Extension. 4. Northland College. 5. University of Wisconsin.Includes bibliographical references

Update on hazelnut development program in the Lake States

Paper presented at the 13th North American Agroforesty Conference, which was held June 19-21, 2013 in Charlottetown, Prince Edward Island, Canada.In Poppy, L., Kort, J., Schroeder, B., Pollock, T., and Soolanayakanahally, R., eds. Agroforestry: Innovations in Agriculture. Proceedings, 13th North American Agroforestry Conference, Charlottetown, Prince Edward Island, Canada, June 19-21, 2013.Hazelnut (Corylus spp.) is a potential nut crop for the Lake States. In the past, researchers and hobbyists have hybridized American and European hazelnut in an effort to develop a cold hardy, disease resistant hybrid hazelnut. There are relatively few varieties available and most plantings are currently seed origin. For pure American hazelnut, there are nearly no available varieties (at this point we know of two). Our goals are to: select high productivity wild hazelnuts, successfully pilot one or more propagation protocols and field test the selected genotypes. A group representing a diversity of disciplines and Upper Midwest States has been selecting American hazelnut from wild populations in Northern Wisconsin for use as parents in controlled crosses as well as potential clonal planting stock. To date, we have screened 35 sites across 10 WI Counties and have selected more than 30 individuals that meet 1% selection criteria on kernel yield per square foot. We are currently micropropagating these individuals for evaluation in replicated germplasm trials. We have also successfully tested mound layering protocols. This is an intermediate general report and specific results will be reported as they become available.Mike Demchik (1), Jason Fischbach (2), Brent McCown (3), Eric Zeldin (3) and Tony Kern (4) ; 1. University of Wisconsin Stevens Point, 800 Reserve Street, Stevens Point, WI, 54481 USA. 2. University of Wisconsin Extension, 117 East 5th St, Washburn, WI, 54891 USA. 3. Department of Horticulture, 1575 Linden Drive, University of Wisconsin-Madison, Madison, WI 53706 USA. 4. Department Chair of Biology and Chemistry, 1501 Morningside Avenue, Morningside College, Sioux City, Iowa 51106, USA.Includes bibliographical references

IV sotalol use in pediatric and congenital heart patients: A multicenter registry study

Background There is limited information regarding the clinical use and effectiveness of IV sotalol in pediatric patients and patients with congenital heart disease, including those with severe myocardial dysfunction. A multicenter registry study was designed to evaluate the safety, efficacy, and dosing of IV sotalol. Methods and Results A total of 85 patients (age 1 day-36 years) received IV sotalol, of whom 45 (53%) had additional congenital cardiac diagnoses and 4 (5%) were greater than 18 years of age. In 79 patients (93%), IV sotalol was used to treat supraventricular tachycardia and 4 (5%) received it to treat ventricular arrhythmias. Severely decreased cardiac function by echocardiography was seen before IV sotalol in 7 (9%). The average dose was 1 mg/kg (range 0.5-1.8 mg/kg/dose) over a median of 60 minutes (range 30-300 minutes). Successful arrhythmia termination occurred in 31 patients (49%, 95% CI [37%-62%]) with improvement in rhythm control defined as rate reduction permitting overdrive pacing in an additional 18 patients (30%, 95% CI [19%-41%]). Eleven patients (16%) had significant QTc prolongation to \u3e465 milliseconds after the infusion, with 3 (4%) to \u3e500 milliseconds. There were 2 patients (2%) for whom the infusion was terminated early. Conclusions IV sotalol was safe and effective for termination or improvement of tachyarrhythmias in 79% of pediatric patients and patients with congenital heart disease, including those with severely depressed cardiac function. The most common dose, for both acute and maintenance dosing, was 1 mg/kg over ~60 minutes with rare serious complications

An acetylcholine receptor lacking both γ and ε subunits mediates transmission in zebrafish slow muscle synapses

Fast and slow skeletal muscle types in larval zebrafish can be distinguished by a fivefold difference in the time course of their synaptic decay. Single-channel recordings indicate that this difference is conferred through kinetically distinct nicotinic acetylcholine receptor (AChR) isoforms. The underlying basis for this distinction was explored by cloning zebrafish muscle AChR subunit cDNAs and expressing them in Xenopus laevis oocytes. Measurements of single-channel conductance and mean open burst duration assigned α2βδε to fast muscle synaptic current. Contrary to expectations, receptors composed of only αβδ subunits (presumed to be α2βδ2 receptors) recapitulated the kinetics and conductance of slow muscle single-channel currents. Additional evidence in support of γ/ε-less receptors as mediators of slow muscle synapses was reflected in the inward current rectification of heterologously expressed α2βδ2 receptors, a property normally associated with neuronal-type nicotinic receptors. Similar rectification was reflected in both single-channel and synaptic currents in slow muscle, distinguishing them from fast muscle. The final evidence for α2βδ2 receptors in slow muscle was provided by our ability to convert fast muscle synaptic currents to those of slow muscle by knocking down ε subunit expression in vivo. Thus, for the first time, muscle synaptic function can be ascribed to a receptor isoform that is composed of only three different subunits. The unique functional features offered by the α2βδ2 receptor likely play a central role in mediating the persistent contractions characteristic to this muscle type

Flecainide Is Associated With a Lower Incidence of Arrhythmic Events in a Large Cohort of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia

BACKGROUND: In severely affected patients with catecholaminergic polymorphic ventricular tachycardia, beta-blockers are often insufficiently protective. The purpose of this study was to evaluate whether flecainide is associated with a lower incidence of arrhythmic events (AEs) when added to beta-blockers in a large cohort of patients with catecholaminergic polymorphic ventricular tachycardia. METHODS: From 2 international registries, this multicenter case cross-over study included patients with a clinical or genetic diagnosis of catecholaminergic polymorphic ventricular tachycardia in whom flecainide was added to beta-blocker therapy. The study period was defined as the period in which background therapy (ie, beta-blocker type [beta1-selective or nonselective]), left cardiac sympathetic denervation, and implantable cardioverter defibrillator treatment status, remained unchanged within individual patients and was divided into pre-flecainide and on-flecainide periods. The primary end point was AEs, defined as sudden cardiac death, sudden cardiac arrest, appropriate implantable cardioverter defibrillator shock, and arrhythmic syncope. The association of flecainide with AE rates was assessed using a generalized linear mixed model assuming negative binomial distribution and random effects for patients. RESULTS: A total of 247 patients (123 [50%] females; median age at start of flecainide, 18 years [interquartile range, 14-29]; median flecainide dose, 2.2 mg/kg per day [interquartile range, 1.7-3.1]) were included. At baseline, all patients used a beta-blocker, 70 (28%) had an implantable cardioverter defibrillator, and 21 (9%) had a left cardiac sympathetic denervation. During a median pre-flecainide follow-up of 2.1 years (interquartile range, 0.4-7.2), 41 patients (17%) experienced 58 AEs (annual event rate, 5.6%). During a median on-flecainide follow-up of 2.9 years (interquartile range, 1.0-6.0), 23 patients (9%) experienced 38 AEs (annual event rate, 4.0%). There were significantly fewer AEs after initiation of flecainide (incidence rate ratio, 0.55 [95% CI, 0.38-0.83]; P=0.007). Among patients who were symptomatic before diagnosis or during the pre-flecainide period (n=167), flecainide was associated with significantly fewer AEs (incidence rate ratio, 0.49 [95% CI, 0.31-0.77]; P=0.002). Among patients with ≥1 AE on beta-blocker therapy (n=41), adding flecainide was also associated with significantly fewer AEs (incidence rate ratio, 0.25 [95% CI, 0.14-0.45]; P&lt;0.001). CONCLUSIONS: For patients with catecholaminergic polymorphic ventricular tachycardia, adding flecainide to beta-blocker therapy was associated with a lower incidence of AEs in the overall cohort, in symptomatic patients, and particularly in patients with breakthrough AEs while on beta-blocker therapy.</p

Minimum Information about a Biosynthetic Gene cluster

A wide variety of enzymatic pathways that produce specialized metabolites in bacteria, fungi and plants are known to be encoded in biosynthetic gene clusters. Information about these clusters, pathways and metabolites is currently dispersed throughout the literature, making it difficult to exploit. To facilitate consistent and systematic deposition and retrieval of data on biosynthetic gene clusters, we propose the Minimum Information about a Biosynthetic Gene cluster (MIBiG) data standard.Chemistry and Chemical Biolog

Rcupcake: an R package for querying and analyzing biomedical data through the BD2K PIC-SURE RESTful API

MOTIVATION: In the era of big data and precision medicine, the number of databases containing clinical, environmental, self-reported and biochemical variables is increasing exponentially. Enabling the experts to focus on their research questions rather than on computational data management, access and analysis is one of the most significant challenges nowadays. RESULTS: We present Rcupcake, an R package that contains a variety of functions for leveraging different databases through the BD2K PIC-SURE RESTful API and facilitating its query, analysis and interpretation. The package offers a variety of analysis and visualization tools, including the study of the phenotype co-occurrence and prevalence, according to multiple layers of data, such as phenome, exposome or genome

Benchmarking in Optimization: Best Practice and Open Issues

This survey compiles ideas and recommendations from more than a dozen researchers with different backgrounds and from different institutes around the world. Promoting best practice in benchmarking is its main goal. The article discusses eight essential topics in benchmarking: clearly stated goals, well- specified problems, suitable algorithms, adequate performance measures, thoughtful analysis, effective and efficient designs, comprehensible presentations, and guaranteed reproducibility. The final goal is to provide well-accepted guidelines (rules) that might be useful for authors and reviewers. As benchmarking in optimization is an active and evolving field of research this manuscript is meant to co-evolve over time by means of periodic updates